Susanne Jacobsson1, Michelle J Cole2, Gianfranco Spiteri3, Michaela Day2, Magnus Unemo4. 1. WHO Collaborating Centre for Gonorrhoea and other STIs, National Reference Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. 2. National Infection Service, Public Health England, Colindale, UK. 3. European Centre for Disease Prevention and Control, Stockholm, Sweden. 4. WHO Collaborating Centre for Gonorrhoea and other STIs, National Reference Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. magnus_unemo@yahoo.com.
Abstract
BACKGROUND: The emergence and spread of antimicrobial resistance (AMR) in Neisseria gonorrhoeae, nationally and internationally, is a serious threat to the management and control of gonorrhoea. Limited and conflicting data regarding the epidemiological drivers of gonococcal AMR internationally have been published. We examined the antimicrobial susceptibility/resistance of gonococcal isolates (n = 15,803) collected across 27 European Union/European Economic Area (EU/EEA) countries in 2009-2016, in conjunction to epidemiological and clinical data of the corresponding patients, to elucidate associations between antimicrobial susceptibility/resistance and patients' gender, sexual orientation and anatomical site of infection. METHODS: In total, 15,803 N. gonorrhoeae isolates from the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), 2009-2016, were examined. Associations between gonococcal susceptibility/resistance and patients' gender, sexual orientation and anatomical site of infection were investigated using univariate and multivariate logistic regression analysis. Statistical significance was determined by Pearson χ2-test or Fisher's exact test with two-tailed p-values of < 0.05 indicating significance. RESULTS: The overall gonococcal resistance from 2009 to 2016 was 51.7% (range during the years: 46.5-63.5%), 7.1% (4.5-13.2%), 4.3% (1.8-8.7%), and 0.2% (0.0-0.5%) to ciprofloxacin, azithromycin, cefixime, and ceftriaxone, respectively. The level of resistance combined with decreased susceptibility to ceftriaxone was 10.2% (5.7-15.5%). Resistance to cefixime and ciprofloxacin, and resistance combined with decreased susceptibility to ceftriaxone were positively associated with urogenital infections and heterosexual males, males with sexual orientation not reported and females (except for ciprofloxacin), i.e. when compared to men-who-have-sex-with-men (MSM). Azithromycin resistance was positively associated with heterosexual males, but no association was significant regarding anatomical site of infection. CONCLUSIONS: Overall, sexual orientation was the main variable associated with gonococcal AMR. Strongest positive associations were identified with heterosexual patients, particularly males, and not MSM. To provide evidence-based understanding and mitigate gonococcal AMR emergence and spread, associations between antimicrobial susceptibility/resistance and patients' gender, sexual orientation and anatomical site of infection need to be further investigated in different geographic settings. In general, these insights will support identification of groups at increased risk and targeted public health actions such as intensified screening, 3-site testing using molecular diagnostics, sexual contact tracing, and surveillance of treatment failures.
BACKGROUND: The emergence and spread of antimicrobial resistance (AMR) in Neisseria gonorrhoeae, nationally and internationally, is a serious threat to the management and control of gonorrhoea. Limited and conflicting data regarding the epidemiological drivers of gonococcal AMR internationally have been published. We examined the antimicrobial susceptibility/resistance of gonococcal isolates (n = 15,803) collected across 27 European Union/European Economic Area (EU/EEA) countries in 2009-2016, in conjunction to epidemiological and clinical data of the corresponding patients, to elucidate associations between antimicrobial susceptibility/resistance and patients' gender, sexual orientation and anatomical site of infection. METHODS: In total, 15,803 N. gonorrhoeae isolates from the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), 2009-2016, were examined. Associations between gonococcal susceptibility/resistance and patients' gender, sexual orientation and anatomical site of infection were investigated using univariate and multivariate logistic regression analysis. Statistical significance was determined by Pearson χ2-test or Fisher's exact test with two-tailed p-values of < 0.05 indicating significance. RESULTS: The overall gonococcal resistance from 2009 to 2016 was 51.7% (range during the years: 46.5-63.5%), 7.1% (4.5-13.2%), 4.3% (1.8-8.7%), and 0.2% (0.0-0.5%) to ciprofloxacin, azithromycin, cefixime, and ceftriaxone, respectively. The level of resistance combined with decreased susceptibility to ceftriaxone was 10.2% (5.7-15.5%). Resistance to cefixime and ciprofloxacin, and resistance combined with decreased susceptibility to ceftriaxone were positively associated with urogenital infections and heterosexual males, males with sexual orientation not reported and females (except for ciprofloxacin), i.e. when compared to men-who-have-sex-with-men (MSM). Azithromycin resistance was positively associated with heterosexual males, but no association was significant regarding anatomical site of infection. CONCLUSIONS: Overall, sexual orientation was the main variable associated with gonococcal AMR. Strongest positive associations were identified with heterosexual patients, particularly males, and not MSM. To provide evidence-based understanding and mitigate gonococcal AMR emergence and spread, associations between antimicrobial susceptibility/resistance and patients' gender, sexual orientation and anatomical site of infection need to be further investigated in different geographic settings. In general, these insights will support identification of groups at increased risk and targeted public health actions such as intensified screening, 3-site testing using molecular diagnostics, sexual contact tracing, and surveillance of treatment failures.
Authors: Eric P F Chow; Marcus Y Chen; Deborah A Williamson; Catriona S Bradshaw; Lenka A Vodstrcil; Sabrina Trumpour; Benjamin P Howden; Christopher K Fairley Journal: Sex Transm Dis Date: 2019-11 Impact factor: 2.830
Authors: Teodora Wi; Monica M Lahra; Francis Ndowa; Manju Bala; Jo-Anne R Dillon; Pilar Ramon-Pardo; Sergey R Eremin; Gail Bolan; Magnus Unemo Journal: PLoS Med Date: 2017-07-07 Impact factor: 11.069
Authors: Simon R Harris; Michelle J Cole; Gianfranco Spiteri; Leonor Sánchez-Busó; Daniel Golparian; Susanne Jacobsson; Richard Goater; Khalil Abudahab; Corin A Yeats; Beatrice Bercot; Maria José Borrego; Brendan Crowley; Paola Stefanelli; Francesco Tripodo; Raquel Abad; David M Aanensen; Magnus Unemo Journal: Lancet Infect Dis Date: 2018-05-15 Impact factor: 71.421
Authors: Edward Goldstein; Robert D Kirkcaldy; David Reshef; Stuart Berman; Hillard Weinstock; Pardis Sabeti; Carlos Del Rio; Geraldine Hall; Edward W Hook; Marc Lipsitch Journal: Emerg Infect Dis Date: 2012-08 Impact factor: 6.883
Authors: David W Eyre; Nicholas D Sanderson; Emily Lord; Natasha Regisford-Reimmer; Kevin Chau; Leanne Barker; Markus Morgan; Robert Newnham; Daniel Golparian; Magnus Unemo; Derrick W Crook; Tim Ea Peto; Gwenda Hughes; Michelle J Cole; Helen Fifer; Anne Edwards; Monique I Andersson Journal: Euro Surveill Date: 2018-07
Authors: Alessio Nocentini; Chad S Hewitt; Margaret D Mastrolorenzo; Daniel P Flaherty; Claudiu T Supuran Journal: J Enzyme Inhib Med Chem Date: 2021-12 Impact factor: 5.051
Authors: Ronza Hadad; Daniel Golparian; Inga Velicko; Anna-Karin Ohlsson; Ylva Lindroth; Eva-Lena Ericson; Hans Fredlund; Lars Engstrand; Magnus Unemo Journal: Front Microbiol Date: 2022-01-13 Impact factor: 5.640